Galectins: emerging regulatory checkpoints linking tumor immunity and angiogenesis
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Immune checkpoints, a plethora of inhibitory pathways aimed at maintaining immune cell homeostasis, may be co-opted by cancer cells to evade immune destruction. Therapies targeting immune checkpoints have reached a momentum yielding significant clinical benefits in patients with various malignancies by unleashing anti-tumor immunity. Galectins, a family of glycan-binding proteins, have emerged as novel regulatory checkpoints that promote immune evasive programs by inducing T-cell exhaustion, limiting T-cell survival, favoring expansion of regulatory T cells, de-activating natural killer cells and polarizing myeloid cells toward an immunosuppressive phenotype. Concomitantly, galectins can trigger vascular signaling programs, serving as bifunctional messengers that couple tumor immunity and angiogenesis. Thus, targeting galectin-glycan interactions may halt tumor progression by simultaneously augmenting antitumor immunity and suppressing aberrant angiogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation
Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096 · cited 11×
“Moreover, galectin-3 dampens antitumor responses through interactions with LAG-3 on the surface of CD8T cells, whereas galectin-9 binds to TIM-3 leading to T-cell exhaustion [9 ,14], an effect that is counteracted by human leukocyte antigen B (HLA-B)-associated transcript 3 (Bat3) [43].”
BackgroundInfluentialCorzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J.-I., Cheng, P., Cho, H.-I., Celis, E., Quiceno, D. G., Padhya, T., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100587 · Cited by 1,173
Lau, K. S., Partridge, E. A., Grigorian, A., Silvescu, C. I., Reinhold, V. N., Demetriou, M., & Dennis, J. W. (2007) · Cell · doi:10.1016/j.cell.2007.01.049 · Cited by 914 · cited 5×
“In this regard, galectin-3-N-glycan complexes trap CTLA-4 on the surface of T cells and prolong inhibitory signals triggered by this immune checkpoint receptor [8].”
BackgroundInfluentialNegative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation
Demetriou, M., Granovsky, M., Quaggin, S., & Dennis, J. W. (2001) · Nature · doi:10.1038/35055582 · Cited by 901 · cited 1×
“Moreover, galectin-3 prevents TCR, CD4 and Lck clustering into GM1enriched membrane microdomains, thereby adjusting T-cell signaling threshold through N-glycan-dependent mechanisms [39,40].”
BackgroundRegulation of Cytokine Receptors by Golgi N-Glycan Processing and Endocytosis
Partridge, E. A., Le Roy, C., Di Guglielmo, G. M., Pawling, J., Cheung, P., Granovsky, M., Nabi, I. R., Wrana, J. L., & Dennis, J. W. (2004) · Science · doi:10.1126/science.1102109 · Cited by 735 · cited 1×
“On the other hand, galectin-3N-glycan lattices enhance the immunosuppressive activity of macrophages by augmenting surface residency of TGF-bR and prolonging delivery of TGF-b-dependent inhibitory signals [63].”
BackgroundToscano, M. A., Bianco, G. A., Ilarregui, J. M., Croci, D. O., Correale, J., Hernandez, J. D., Zwirner, N. W., Poirier, F., Riley, E. M., Baum, L. G., et al. (2007) · Nature Immunology · doi:10.1038/ni1482 · Cited by 653 · cited 2×
“This glycan profile, which facilitates galectin binding to vascular cells, recapitulates that found on Th1-differentiated and Th17-differentiated cells [45], mature DCs [16,69] and M1-polarized microglia/macrophages [11] suggesting the occurrence of common glycan profiles governing both immune and vascular programs.”
BackgroundSelf-citationKouo, T., Huang, L., Pucsek, A. B., Cao, M., Solt, S., Armstrong, T., & Jaffee, E. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0150 · Cited by 531
Rangachari, M., Zhu, C., Sakuishi, K., Xiao, S., Karman, J., Chen, A., Angin, M., Wakeham, A., Greenfield, E. A., Sobel, R. A., et al. (2012) · Nature Medicine · doi:10.1038/nm.2871 · Cited by 394
Rutkowski, M. R., Stephen, T. L., Svoronos, N., Allegrezza, M. J., Tesone, A. J., Perales-Puchalt, A., Brencicova, E., Escovar-Fadul, X., Nguyen, J. M., Cadungog, M. G., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.009 · Cited by 311
Self-citationMatarrese, P., Tinari, A., Mormone, E., Bianco, G. A., Toscano, M. A., Ascione, B., Rabinovich, G. A., & Malorni, W. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m409752200 · Cited by 182 · cited 1×
“Galectin-1 triggers T-cell apoptosis through binding to N-glycans and O-glycans on CD45, CD43 and CD7 or by sensitizing resting T cells to Fas-induced death [10,44].”
BackgroundSelf-citation
Cited by
Johannes, L., Jacob, R., & Leffler, H. (2018) · Journal of Cell Science · doi:10.1242/jcs.208884 · Cited by 618
The extracellular matrix in tumor progression and metastasis
Eble, J. A., & Niland, S. (2019) · Clinical & Experimental Metastasis · doi:10.1007/s10585-019-09966-1 · Cited by 613
The tumour glyco-code as a novel immune checkpoint for immunotherapy
RodrÍguez, E., Schetters, S. T. T., & van Kooyk, Y. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2018.3 · Cited by 473
Albini, A., Bruno, A., Noonan, D. M., & Mortara, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00527 · Cited by 392
Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z
Sciacchitano, S., Lavra, L., Morgante, A., Ulivieri, A., Magi, F., De Francesco, G., Bellotti, C., Salehi, L., & Ricci, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020379 · Cited by 377
Metadata
- Authors
- Méndez-Huergo, S. P., Blidner, A. G., & Rabinovich, G. A.
- Venue
- Current Opinion in Immunology
- Publisher
- Elsevier BV
- Published
- 2017-04
- Volume
- 45
- Pages
- 8-15
- ISSN
- 0952-7915 (ISSN-L)
- OpenAlex
- W2574278005
- Cited by
- 152
- References
- 11
- FWCI
- 1.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.